- Home
- NEWP vs SLS Comparison
NEWP vs SLS Comparison
Compare NEWP & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEWP
- SLS
- Stock Information
- Founded
- NEWP 1972
- SLS 2012
- Country
- NEWP Canada
- SLS United States
- Employees
- NEWP N/A
- SLS N/A
- Industry
- NEWP
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- NEWP
- SLS Health Care
- Exchange
- NEWP Nasdaq
- SLS Nasdaq
- Market Cap
- NEWP 199.1M
- SLS 169.6M
- IPO Year
- NEWP N/A
- SLS N/A
- Fundamental
- Price
- NEWP $1.45
- SLS $1.72
- Analyst Decision
- NEWP Strong Buy
- SLS
- Analyst Count
- NEWP 1
- SLS 0
- Target Price
- NEWP $5.00
- SLS N/A
- AVG Volume (30 Days)
- NEWP 262.4K
- SLS 3.0M
- Earning Date
- NEWP 05-07-2025
- SLS 05-13-2025
- Dividend Yield
- NEWP N/A
- SLS N/A
- EPS Growth
- NEWP N/A
- SLS N/A
- EPS
- NEWP N/A
- SLS N/A
- Revenue
- NEWP N/A
- SLS N/A
- Revenue This Year
- NEWP N/A
- SLS N/A
- Revenue Next Year
- NEWP N/A
- SLS N/A
- P/E Ratio
- NEWP N/A
- SLS N/A
- Revenue Growth
- NEWP N/A
- SLS N/A
- 52 Week Low
- NEWP $0.93
- SLS $0.77
- 52 Week High
- NEWP $2.11
- SLS $2.12
- Technical
- Relative Strength Index (RSI)
- NEWP 66.49
- SLS 54.71
- Support Level
- NEWP $1.35
- SLS $1.66
- Resistance Level
- NEWP $1.46
- SLS $2.12
- Average True Range (ATR)
- NEWP 0.08
- SLS 0.18
- MACD
- NEWP 0.02
- SLS -0.02
- Stochastic Oscillator
- NEWP 96.23
- SLS 47.37
About NEWP New Pacific Metals Corp.
New Pacific Metals Corp is a Canadian Mining Issuer, in the business of exploring and developing precious metal properties in Bolivia. The company's projects which are also its reportable segments include Silver Sand; Carangas and Silverstrike.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.